TAO Synergies TAOX
NASDAQ TAOX
$4.12 +0.11 (+2.74%)
As of: Sep 9, 2026 · 12:29 PM EDT

TAO Synergies (TAOX) Cash & Equivalents (2019 - 2026)

TAO Synergies' (TAOX) quarterly Cash & Equivalents came in at $2.4 million in Q2 2026, down 83.33% on a YoY basis from $14.4 million in Q2 2025, and down 34.17% quarter-over-quarter from $3.6 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Cash & Equivalents (2019 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Cash & Equivalents for 8 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash & Equivalents fell 83.33% year-over-year to $2.4 million; the trailing twelve-month figure through Jun 2026 stood at $2.4 million (down 83.33% YoY), and the FY2025 full-year result was $5.5 million, down 68.94% from the prior year.
  • Cash & Equivalents retreated to $2.4 million in Q2 2026 per TAOX's latest filing, from $3.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $37.5 million in Q4 2022 and bottomed at $2.4 million in Q2 2026.
  • Historically, Cash & Equivalents has averaged $22.5 million across 5 years, with a median of $26.3 million in 2024.
  • The sharpest annual moves came in 2022 and 2026: Cash & Equivalents surged 110.8% in 2022, then plunged 83.33% in 2026.
  • Over 5 years, Cash & Equivalents stood at $37.5 million in 2022, then decreased by 23.47% to $28.7 million in 2023, then tumbled by 38.33% to $17.7 million in 2024, then sank by 68.94% to $5.5 million in 2025, then plunged by 56.35% to $2.4 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods registered $2.4 million, $3.6 million, and $5.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Amgen 211.50 Bn 197.51 Bn 7.24 Bn 13.99 Bn
2 Gilead Sciences 181.29 Bn 178.11 Bn 6.22 Bn 3.18 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 6.14 Bn
4 Regeneron Pharmaceuticals 82.55 Bn 74.56 Bn 3.93 Bn 2.46 Bn
5 Argenx Se 61.65 Bn 56.47 Bn 1.37 Bn 3.58 Bn
6 Moderna 54.65 Bn 49.52 Bn 52.00 Mn 1.72 Bn
7 Alnylam Pharmaceuticals 34.18 Bn 30.87 Bn 992.69 Mn 1.71 Bn
8 Biogen 31.36 Bn 30.07 Bn 1.96 Bn 1.29 Bn
9 Roivant Sciences 30.01 Bn 30.01 Bn 1.16 Mn 1.25 Bn
10 TAO Synergies 30.79 Mn 30.79 Mn - 2.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.40 Mn
Mar 31, 2026 3.65 Mn
Dec 31, 2025 5.50 Mn
Jun 30, 2025 14.40 Mn
Mar 31, 2025 14.83 Mn
Dec 31, 2024 17.70 Mn
Sep 30, 2024 19.63 Mn
Jun 30, 2024 25.00 Mn
Mar 31, 2024 26.33 Mn
Dec 31, 2023 28.70 Mn
Sep 30, 2023 31.73 Mn
Jun 30, 2023 32.90 Mn
Mar 31, 2023 35.80 Mn
Dec 31, 2022 37.50 Mn
Sep 30, 2022 26.33 Mn
Jun 30, 2022 28.80 Mn
Mar 31, 2022 31.30 Mn
Dec 31, 2021 34.21 Mn
Sep 30, 2021 31.30 Mn
Jun 30, 2021 31.70 Mn